Neuronetics, Inc , a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally.
infoNeuronetics is a micro cap stock with a total market cap of 46.20M.
infoThey trade on the NASDAQ and had their IPO 5 years and 1 month ago.
infoNeuronetics currently employs 209 people.
infoAs of Wednesday, Aug 23 2023, Neuronetics’s share price is $1.6.
News Relating to Neuronetics
Seeking Alpha
Neuronetics, Inc. (STIM) Q2 2023 Earnings Call Transcript
Tuesday Aug 08 2023 at 12:59
Neuronetics, Inc. (NASDAQ:STIM ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 PM ET Company Participants Mark Klausner – ICR Westwicke Keith Sullivan – President and Chief Executive Officer Steve Furlong – Chief Financial Officer Conference Call Participants Margaret Kaczor – William Blair Zachary Day – Canaccord Simran Kaur – Piper Sandler Daniel Stauder – JMP Securities Operator Thank you for standing by, welcome to the Neuronetics Second Quarter 2023 Financial and Operating Results Conference Call. At this time al participants’ are in a listen-only mode.
GlobeNewsWire
Neuronetics to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call
Tuesday Jul 25 2023 at 08:30
MALVERN, Pa., July 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2023 financial and operating results prior to market open on Tuesday, August 8th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
GlobeNewsWire
Neuronetics to Present at the William Blair 43rd Annual Growth Stock Conference
Wednesday May 24 2023 at 16:30
MALVERN, Pa., May 24, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “company” or “Neuronetics”), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, announced that the management team will present at the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023. The Company is scheduled to present at 1:00 pm Eastern Time the same day via webcast.
Seeking Alpha
Neuronetics, Inc. (STIM) Q1 2023 Earnings Call Transcript
Saturday May 13 2023 at 12:13
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2023 Earnings Conference Call May 13, 2023 8:30 AM ET Company Participants Mark Klausner – ICR Westwicke Keith Sullivan – President and Chief Executive Officer Steve Furlong – Chief Financial Officer Operator Thank you for standing by, and welcome to the Neuronetics First Quarter 2023 Financial and Operating Results. [Operator Instructions] As a reminder, today’s program is being recorded.
GlobeNewsWire
Neuronetics to Present at the JMP Securities Life Sciences Conference
Tuesday May 09 2023 at 17:00
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023. The Company is scheduled to present at 12:30 pm Eastern Time the same day via webcast.
GlobeNewsWire
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
Tuesday Apr 25 2023 at 08:30
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
24/7 Wall Street
Cannell Capital Now Owns 11.03% of Neuronetics
Thursday Mar 23 2023 at 22:21
Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).
Zacks Investment Research
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Mar 07 2023 at 09:47
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
Wednesday Feb 22 2023 at 16:35
MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter 2022 financial and operating results prior to market open on Tuesday, March 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Seeking Alpha
Why I Am Passing On BrainsWay And Neuronetics
Friday Feb 17 2023 at 11:46
I am bullish on the niche industry that uses magnetic stimulation for brain therapies. BrainsWay and Neuronetics are US-listed stocks in this niche, however they are highly unprofitable with volatile sales growth.
Seeking Alpha
Neuronetics: An Overdue Checkup
Monday Feb 13 2023 at 14:29
Today, we revisit a small medical device company called Neuronetics for the first time since January 2021. The stock is up some 30% over that time as Neuronetics has seen some notable milestones and delivered consistent sales growth.
Zacks Investment Research
Is Neuronetics (STIM) Stock Outpacing Its Medical Peers This Year?
Friday Dec 23 2022 at 11:17
Here is how Neuronetics (STIM) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Zacks Investment Research
Neuronetics (STIM) Is Up 12.75% in One Week: What You Should Know
Tuesday Dec 06 2022 at 13:33
Does Neuronetics (STIM) have what it takes to be a top stock pick for momentum investors? Let’s find out.
Seeking Alpha
Neuronetics: Numerous Expansion Opportunities Mean An Outperforming Stock
Monday Nov 28 2022 at 14:07
The high prevalence of major depressive disorder creates the need for Neuronetics’ NeuroStar Advanced Therapy System. Neuronetics is valued below its industry, leaving plenty of room to the upside for the stock.
GlobeNewsWire
Neuronetics to Present at the Piper Sandler 34th Annual Healthcare Conference
Monday Nov 21 2022 at 16:30
MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com . A replay of the webcast will be archived on the website for approximately 90 days. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, http://www.neurostar.com. Investor Contact: Mark KlausnerWestwicke Partners443-213-0501 ir@neuronetics.com Media Contact: EvolveMKD646.517.4220 NeuroStar@evolvemkd.com
Zacks Investment Research
New Strong Buy Stocks for November 16th
Wednesday Nov 16 2022 at 09:02
ENTX, STIM, FN, ANGN and FUTU have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2022.
Seeking Alpha
Neuronetics, Inc. (STIM) Q3 2022 Earnings Call Transcript
Friday Nov 11 2022 at 13:00
Neuronetics, Inc. (NASDAQ:STIM ) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Mark Klausner – ICR Westwicke Keith Sullivan – President and Chief Executive Officer Stephen Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Margaret Kaczor – William Blair Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day and thank you for standing by. Welcome to the Neuronetics Report Third Quarter 2022 Financial and Operating Results Conference Call.
GlobeNewsWire
Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call
Tuesday Oct 25 2022 at 08:30
MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter 2022 financial and operating results prior to market open on Tuesday, November 8th, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/h3amkwib. To listen to the conference call on your telephone, participants may register for the call here . While it is not required, it is recommended you join 10 minutes prior to the event start. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, http://www.neurostar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Westwicke443-213-0499ir@neuronetics.com Media Contact: EvolveMKD646-517-4220NeuroStar@evolvemkd.com
Seeking Alpha
Neuronetics Inc (STIM) CEO Keith Sullivan on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 02 2022 at 12:52
Neuronetics Inc (NASDAQ:STIM ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President & CEO Steve Furlong – SVP, CFO & Treasurer Conference Call Participants Adam Maeder – Piper Sandler Margaret Kaczor – William Blair William Plovanic – Canaccord Genuity Marie Thibault – BTIG David Turkaly – JMP Securities Operator Good day, and thank you for standing by. Welcome to the Neuronetics’ Reports Second Quarter 2022 Financial and Operating Results Conference Call.
GlobeNewsWire
Neuronetics to Present at the Canaccord Genuity 42nd Annual Growth Conference
Thursday Jul 28 2022 at 16:30
MALVERN, Pa., July 28, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022. The Company is scheduled to present at 11:30 am Eastern Time the same day via webcast.
Market Watch
Neuronetics gets another FDA clearance for transcranial magnetic stimulation system; shares jump 22%
Tuesday Jul 19 2022 at 08:57
Shares of Neuronetics Inc. STIM, -6.67% gained 22.5% in premarket trading on Tuesday after the company said it received clearance from the Food and Drug Administration to market its transcranial magnetic stimulation system as a treatment for anxiety in adults with major depressive disorder. The system was previously cleared to treat obsessive-compulsive disorder.
GlobeNewsWire
Neuronetics to Report Second Quarter 2022 Financial and Operating Results and Host Conference Call
Tuesday Jul 19 2022 at 08:30
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release second quarter 2022 financial and operating results prior to market open on Tuesday, August 2nd, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Benzinga
Read Why Neuronetics Shares Are Trading Higher Today
Tuesday Jul 19 2022 at 08:00
The FDA has cleared Neuronetics Inc’s (NASDAQ: STIM) NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients with major depressive disorder (MDD), also known as anxious depression. NeuroStar is a patient-focused Transcranial magnetic.
GlobeNewsWire
Neuronetics to Present at the William Blair 42nd Annual Growth Stock Conference
Wednesday May 25 2022 at 16:30
MALVERN, Pa., May 25, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurological health disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the William Blair 42nd Annual Growth Stock Conference. The Company is scheduled to present on Wednesday, June 8, 2022 at 2:20pm ET.
Seeking Alpha
Neuronetics’ (STIM) CEO Keith Sullivan on Q1 2022 Results – Earnings Call Transcript
Thursday May 12 2022 at 12:35
Neuronetics, Inc. (NASDAQ:STIM ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Mark Klausner – Investor Relations Keith Sullivan – President and Chief Executive Officer Steve Furlong – Senior Vice President, Chief Financial Officer and Treasurer Conference Call Participants Adam Maeder – Piper Sandler Bill Plovanic – Canaccord Marie Thibault – BTIG Operator Good day, and thank you for standing by. Welcome to the Neuronetics First Quarter 2022 Financial and Operating Results Conference Call.
Benzinga
Executives Buy Around $1M Of 4 Penny Stocks
Tuesday Apr 05 2022 at 14:13
The ISM services PMI rose to 58.3 in March from 56.5 in the previous month. Investors, meanwhile, focused on some notable insider trades.
Benzinga
Neuronetics Posts Better Than Expected Q4 Results Despite Lower NeuroStar Therapy System Sales
Tuesday Mar 08 2022 at 15:16
Neuronetics Inc (NASDAQ: STIM) reported Q4 FY21 sales of $15.02 million, down 4% Y/Y, exceeding previously issued guidance of $13.0 million – $14.0 million and the consensus of $14.43 million. U.S. revenue decreased by 3% during the quarter, and international revenue decreased by 13% Y/Y.
Seeking Alpha
Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2021 Earnings Call Transcript
Tuesday Mar 08 2022 at 13:43
Neuronetics, Inc. (STIM) CEO Keith Sullivan on Q4 2021 Earnings Call Transcript
Zacks Investment Research
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Mar 08 2022 at 10:32
Neuronetics (STIM) delivered earnings and revenue surprises of 12.12% and 2.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Neuronetics to Report Fourth Quarter and Fiscal Year 2021 Financial and Operating Results and Host Conference Call
Tuesday Feb 22 2022 at 16:30
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter and fiscal year 2021 financial and operating results prior to market open on Tuesday, March 8, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Neuronetics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Neuronetics’s Altman Z-score is -4.18 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Neuronetics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $13.36K of common stock in Neuronetics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Neuronetics’s Income Quality of 0.88 is greater than its Industry Group of 0.68 (29.4% greater)
Neuronetics’s Income Quality of 0.88 is greater than its Major Industry Group of 0.71 (23.9% greater)
Neuronetics’s Income Quality of 0.88 is greater than its Sector of 0.75 (17.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Neuronetics’s Current Ratio of 5.17 is greater than its Industry Group of 3.36 (53.9% greater)
Neuronetics’s Current Ratio of 5.17 is greater than its Major Industry Group of 3.13 (65.2% greater)
Neuronetics’s Current Ratio of 5.17 is greater than its Sector of 2.6 (98.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.41 & -1.02)
Cannot compare a negative PE Ratio (-1.41 & -0.58)
Cannot compare a negative PE Ratio (-1.41 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Neuronetics’s PB Ratio of 1.02 is lower than its Industry Group of 1.9 (-46.3% lower)
Neuronetics’s PB Ratio of 1.02 is lower than its Major Industry Group of 1.93 (-47.2% lower)
Neuronetics’s PB Ratio of 1.02 is lower than its Sector of 1.62 (-37.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Neuronetics’s ROE of -0.72 is lower than its Industry Group of -0.26 (-176.9% lower)
Neuronetics’s ROE of -0.72 is lower than its Major Industry Group of -0.09 (-700.0% lower)
Neuronetics’s ROE of -0.72 is lower than its Sector of -0.03 (-2300.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Neuronetics’s ROCE of -0.38 is lower than its Industry Group of -0.27 (-40.7% lower)
Neuronetics’s ROCE of -0.38 is lower than its Major Industry Group of -0.14 (-171.4% lower)
Neuronetics’s ROCE of -0.38 is lower than its Sector of -0.04 (-850.0% lower)
Derived from SEC.GOV filing dataopen_in_new